You are here

  • Home
  • Online First
  • Efficacy and safety of therapies for Still’s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still’s disease

Article info

Article menu
Inflammatory arthritis
Efficacy and safety of therapies for Still’s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still’s disease

Authors

  • Sara Bindoli Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy PubMed articlesGoogle scholar articles
  • Arianna De Matteis Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, ERN-RITA center, Roma, Italy PubMed articlesGoogle scholar articles
  • Stéphane Mitrovic Department of Rheumatology, Pitié-Salpêtriere Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, FranceCRI-IMIDIATE Clinical Research Network and ERN Rita, CEREMAIA Reference Center, Paris, France PubMed articlesGoogle scholar articles
  • Bruno Fautrel Department of Rheumatology, Pitié-Salpêtriere Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, FranceCRI-IMIDIATE Clinical Research Network and ERN Rita, CEREMAIA Reference Center, Paris, FrancePierre Louis Institute of Epidemiology and Public Health, INSERM UMR-S 1136, Paris, France PubMed articlesGoogle scholar articles
  • Loreto Carmona Instituto de Salud Musculoesquelética (INMUSC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Fabrizio De Benedetti Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, ERN-RITA center, Roma, Italy PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Sara Bindoli; sara.bindoli{at}unipd.it
View Full Text

Citation

Bindoli S, De Matteis A, Mitrovic S, et al
Efficacy and safety of therapies for Still’s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still’s disease
Annals of the Rheumatic Diseases Published Online First: 24 September 2024. doi: 10.1136/ard-2024-225854

Publication history

  • Received March 21, 2024
  • Accepted June 18, 2024
  • First published September 24, 2024.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© European Alliance of Associations for Rheumatology, EULAR 2024. Re-use permitted under CC BY-NC-ND. No commercial re-use. No derivatives. See rights and permissions. Published by BMJ on behalf of EULAR. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.